ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 55.46 Million EUR | 18.71% |
| 2022 | 46.72 Million EUR | -12.58% |
| 2021 | 53.44 Million EUR | 57.28% |
| 2020 | 33.98 Million EUR | 63.82% |
| 2019 | 20.74 Million EUR | 90.3% |
| 2018 | 10.9 Million EUR | 4060.31% |
| 2017 | 262 Thousand EUR | -89.62% |
| 2016 | 2.52 Million EUR | -26.07% |
| 2015 | 3.41 Million EUR | 63.39% |
| 2014 | 2.08 Million EUR | -9.95% |
| 2013 | 2.32 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 111.14 Million EUR | 0.0% |
| 2023 Q2 | 34.68 Million EUR | 0.0% |
| 2023 FY | 55.46 Million EUR | 18.71% |
| 2023 Q4 | 55.46 Million EUR | 0.0% |
| 2022 Q4 | 46.72 Million EUR | 0.0% |
| 2022 Q2 | 49.47 Million EUR | 0.0% |
| 2022 FY | 46.72 Million EUR | -12.58% |
| 2021 FY | 53.44 Million EUR | 57.28% |
| 2021 Q4 | 53.44 Million EUR | 0.0% |
| 2021 Q2 | 31.79 Million EUR | 0.0% |
| 2020 Q4 | 33.98 Million EUR | 0.0% |
| 2020 Q2 | 24.48 Million EUR | 0.0% |
| 2020 FY | 33.98 Million EUR | 63.82% |
| 2019 FY | 20.74 Million EUR | 90.3% |
| 2019 Q2 | 21.8 Million EUR | 0.0% |
| 2019 Q4 | 20.74 Million EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 FY | 10.9 Million EUR | 4060.31% |
| 2018 Q4 | 10.9 Million EUR | 0.0% |
| 2017 Q2 | 331 Thousand EUR | 0.0% |
| 2017 FY | 262 Thousand EUR | -89.62% |
| 2017 Q4 | 262 Thousand EUR | 0.0% |
| 2016 Q4 | 316 Thousand EUR | 0.0% |
| 2016 Q2 | 386 Thousand EUR | 0.0% |
| 2016 FY | 2.52 Million EUR | -26.07% |
| 2015 Q2 | 574 Thousand EUR | 0.0% |
| 2015 Q4 | 405 Thousand EUR | 0.0% |
| 2015 FY | 3.41 Million EUR | 63.39% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | 2.08 Million EUR | -9.95% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q4 | 2.08 Million EUR | 0.0% |
| 2013 FY | 2.32 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1536.106% |
| Adocia SA | 13.08 Million EUR | -323.778% |
| Aelis Farma SA | 4.03 Million EUR | -1273.551% |
| Biophytis S.A. | 8.27 Million EUR | -570.665% |
| Advicenne S.A. | 17.42 Million EUR | -218.301% |
| genOway Société anonyme | 7.23 Million EUR | -666.776% |
| IntegraGen SA | 1.12 Million EUR | -4831.295% |
| Medesis Pharma S.A. | 1.2 Million EUR | -4522.0% |
| Neovacs S.A. | 650 Thousand EUR | -8432.923% |
| NFL Biosciences SA | 62.17 Thousand EUR | -89107.707% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1173.129% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1941.49% |
| Sensorion SA | 2.86 Million EUR | -1833.361% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1422.473% |
| TME Pharma N.V. | 1.16 Million EUR | -4656.775% |
| Valbiotis SA | 6.87 Million EUR | -706.397% |
| TheraVet SA | 1.15 Million EUR | -4681.928% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -516.404% |
| argenx SE | 18.1 Million EUR | -206.342% |
| BioSenic S.A. | 28.16 Million EUR | -96.953% |
| Celyad Oncology SA | 902 Thousand EUR | -6049.002% |
| DBV Technologies S.A. | 13.01 Million USD | -326.036% |
| Galapagos NV | 9.59 Million EUR | -477.991% |
| Genfit S.A. | 70.17 Million EUR | 20.967% |
| GeNeuro SA | 7.73 Million EUR | -616.793% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -947.677% |
| Innate Pharma S.A. | 39.89 Million EUR | -39.032% |
| Inventiva S.A. | 37.4 Million EUR | -48.272% |
| MaaT Pharma SA | 14.07 Million EUR | -294.06% |
| MedinCell S.A. | 58.96 Million EUR | 5.931% |
| Nanobiotix S.A. | 50.56 Million EUR | -9.689% |
| Onward Medical N.V. | 16.87 Million EUR | -228.695% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -305.224% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -21.098% |
| Oxurion NV | 12.33 Million EUR | -349.684% |
| Pharming Group N.V. | 155.29 Million EUR | 64.284% |
| Poxel S.A. | 46.9 Million EUR | -18.26% |
| GenSight Biologics S.A. | 18.42 Million EUR | -200.977% |
| Transgene SA | 1.25 Million EUR | -4312.411% |
| Financière de Tubize SA | 79.2 Million EUR | 29.97% |
| UCB SA | 3.03 Billion EUR | 98.174% |
| Valneva SE | 208.81 Million EUR | 73.439% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -145857.895% |